SCHEMBL14827772

SCHEMBL14827772

Cc1cccc(N2CCC(Nc3ccccc3C)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KB1 P23443 1/20 0.49
▸ ADRB1 P08588 1/20 0.48
▸ KCNH2 Q12809 2/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ NOTUM Q6P988 1/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ RECQL P46063 1/20 0.44
▸ NPY5R Q15761 1/20 0.44
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ POLB P06746 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.43
▸ CCNE1 P24864 1/20 0.42
▸ CDK2 P24941 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA2 P00918 1/20 0.41
▸ CA9 Q16790 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9982556 0.86 MAPT (0.50) RPS6KB1ADRB1KCNH2ALDH1A1MAPT
SCHEMBL9982465 0.81 MAPT (0.55) RPS6KB1ALDH1A1MAPTRAB9ANOTUM
SCHEMBL5538942 0.79 ME3 (0.50) ALDH1A1MAPTRAB9AMEN1KMT2A
SCHEMBL5538936 0.79 MEN1 (0.44) ALDH1A1MAPTRAB9AMAPK1MEN1
SCHEMBL26268468 0.76 POLB (0.49) ALDH1A1MEN1KMT2APOLB
SCHEMBL5202907 0.75 MAPT (0.47) ALDH1A1MAPTRAB9AMAPK1
SCHEMBL13394719 0.74 EPHX2 (0.41) ALDH1A1MAPTMAPK1MEN1KMT2A
SCHEMBL8054516 0.74 ADRB1 (0.61) ADRB1KCNH2ALDH1A1MAPTRAB9A
SCHEMBL11103700 0.73 ADRB1 (0.74) ADRB1KCNH2ALDH1A1MAPTRAB9A
SCHEMBL10373770 0.73 ADRB1 (0.74) ADRB1KCNH2ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES NOVARTIS AG (CH) 2013-04-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085161-A1 PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES IGF1R, IGFBP1, IGFBP2 RPS6KB1 124/4885ADRB1 122/4885KCNH2 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback